<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002416</url>
  </required_header>
  <id_info>
    <org_study_id>298A</org_study_id>
    <nct_id>NCT00002416</nct_id>
  </id_info>
  <brief_title>Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination</brief_title>
  <official_title>A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Triangle Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when&#xD;
      given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to one of two arms in a 2:1 ratio (weighted to Arm 1). Arm 1: Replace&#xD;
      lamivudine with FTC while continuing on current background regimen. Arm 2: Continue on&#xD;
      current lamivudine-containing regimen. Patients are further stratified based upon screening&#xD;
      plasma HIV-1 RNA and background therapy. Stratum 1: Less than 50 copies/ml; PI (protease&#xD;
      inhibitor) in treatment regimen. Stratum 2: Less than 50 copies/ml; NNRTI (nonnucleoside&#xD;
      reverse transcriptase inhibitor) in treatment regimen. Stratum 3: 50-400 copies/ml; PI in&#xD;
      treatment regimen. Stratum 4: 50-400 copies/ml; NNRTI in treatment regimen. Clinic visits&#xD;
      occur at regular intervals throughout the 48-week study period to determine viral load.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>390</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        You may be eligible for this study if you:&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Are HIV-positive.&#xD;
&#xD;
          -  Have a viral load below 400 copies/ml.&#xD;
&#xD;
          -  Agree to use a barrier method of birth control (such as condoms) during the study.&#xD;
&#xD;
          -  Have taken one of the following anti-HIV drug combinations: (1) 3TC plus d4T or ZDV&#xD;
             plus a protease inhibitor (PI) for at least 8 weeks, or (2) 3TC plus d4T or ZDV plus a&#xD;
             nonnucleoside reverse transcriptase inhibitor (NNRTI) for at least 12 weeks. (You must&#xD;
             show the date you started on this combination.)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        You will not be eligible for this study if you:&#xD;
&#xD;
          -  Have had severe diarrhea or have been unable to eat as much as you need due to nausea,&#xD;
             vomiting, or stomachache within 30 days of study entry.&#xD;
&#xD;
          -  Have had a serious medical event within 30 days prior to study entry.&#xD;
&#xD;
          -  Are taking hydroxyurea.&#xD;
&#xD;
          -  Have Grade 2 or higher peripheral neuropathy.&#xD;
&#xD;
          -  Abuse alcohol or drugs.&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles van der Horst</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Dr Robert Wallace</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Univ Hosp</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2000</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Zalcitabine</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Stavudine</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

